Basic Information
| LncRNA/CircRNA Name | AX800134 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, in vitro knockdown, RNAi |
| Sample | hepatocellular carcinoma tissues, blood samples, cell lines (HepG2) |
| Expression Pattern | up-regulated |
| Function Description | The upregulated expression of AX800134 in HBV-positive HCC compared with HBV-negative HCC. Furthermore, we found that HBV X protein (HBx) directly triggered AX800134 expression in human hepatoma HepG2 cells. Pro-inflammatory cytokine TNF? also induced AX800134 upregulation in HBx-expressing HepG2 cells, which could be reversed by reactive oxygen species (ROS) scavenger pyrrolidine dithiocarbamate (PDTC). Additionally, silencing AX800134 with siRNA interference remarkably inhibited the growth and invasion of HBx-expressing HepG2 cells. AX800134 antagonism also enhanced spontaneous apoptosis of HepG2 cells under serum deprivation condition. |
| Pubmed ID | 29789998 |
| Year | 2018 |
| Title | The Expression and Role of lncRNA AX800134 in Hepatitis B Virus-Related Hepatocellular Carcinoma |
External Links
| Links for AX800134 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |